Primary chemoresistance represents a significant unmet clinical need in ovarian cancer treatment. We discovered and independently validated a reactive stroma signature characterizing primary chemoresistant tumors and demonstrated this signature can predict clinical outcomes of first-line chemotherapy. Our study represents the first report to characterize the reactive stroma as the key component in orchestrating chemoresistance in ovarian cancer. This study sets up the stage for identifying primary chemosesistant ovarian cancer patients and developing novel therapeutic strategies to overcome chemoresistance.
Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death for gynecologic malignancies and treatment of EOC continues to present as a significant clinical challenge (1) . The current standard of care for EOC consists of aggressive surgical cytoreduction followed by adjuvant platinum and taxane-based chemotherapy. Although response rates to the first-line treatment are high, 20-30% of cases exhibit intrinsic chemo-refractory or resistance and progress during or within six months of completion of primary therapy (2) . These patients gain little benefit from the standard treatment and represent a significant unmet clinical need in ovarian cancer management. In order to predict response to chemotherapy and develop novel strategies to overcome primary chemo-resistance, a better understanding of the molecular characteristics associated with such intrinsic chemo-resistance is needed.
Activation of the host stromal microenvironment, commonly referred as to "reactive stroma", has been implicated as a critical component of carcinoma progression in many types of cancers (3) (4) (5) (6) . Reactive stroma in cancer has similarities to the biology of the wound healing process in normal tissues, where stromal cells exhibit elevated production of extracellular matrix (ECM) components, growth factors and matrix remodeling enzymes to create a tumor microenvironment that promotes cancer cell survival, proliferation, and invasion (7) . In particular, the tumor microenvironment has been increasingly recognized to play an important role in the pathogenesis of EOC (8, 9) . Unlike many other types of cancers, distant metastasis via hematogenous routes is rare in EOC; instead, EOC cells typically spread within the peritoneal cavity through dissemination of tumor cells into the peritoneal fluid, followed by implantation on the mesothelial linings of the omentum and other peritoneal surfaces that overlie connective and adipose tissues (10) . As a result, the growth and spreading of EOC are likely to be orchestrated Author Manuscript Published OnlineFirst on April 2, 2015; DOI: 10.1158/1078-0432.CCR- by dynamic interplay between tumor cells and the local microenvironment. However, the key regulators of reactive stroma and the specific mechanisms through which reactive stroma affect tumor progression, treatment response and clinical outcomes in EOC are poorly understood.
In this study, we describe the discovery of a distinct reactive stroma signature that is specifically associated with primary chemoresistance in ovarian cancer and further up-regulated in recurrent tumors post progression of chemotherapy. In situ analysis of several key components of this signature, including periostin (POSTN), fibroblast activating protein (FAP) and lysyl oxidase (LOX), revealed that they are specifically up-regulated in the tumor-associated fibroblasts in chemoresistant tumors. We further investigated the specific role of POSTN in promoting chemoresistance in ovarian cancer cells in vitro. Finally, we validated the reactive stroma signature in an independent dataset from the chemo-treatment arm of ICON7 Phase III trial and demonstrated that high expression of POSTN and other components of the signature were associated with shorter progression free survival in response to front line chemotherapy.
This study serves as a springboard for identifying primary chemoresistant ovarian cancer patients and developing novel therapeutic strategies to overcome chemoresistance.
Research. 
Materials and Methods

Patients and tumor specimens
Clinical characteristics of the discovery set of 85 and validation set of 138 high-grade serous and endometrioid ovarian tumors can be found in Table 1, Table 2, Table S6 , described in the Results section and in the Online Materials and Methods. All discovery set tissue samples were obtained from commercial sources and had appropriate IRB approval. The validation set was from the chemo-treatment arm of a phase III trial, ICON7.All tumor tissues were subjected to review by a pathologist to confirm diagnosis and tumor content. Macro-dissection was performed on FFPE tumor tissue to enrich tumor percentage to greater than 70%. Total RNA was purified using High Pure FFPE RNA Micro Kit (Roche Diagnostics, Indianapolis, IN, USA). FFPE tumor DNA was prepared by QIAamp DNA FFPE Tissue Kit (Qiagen, CA).
Gene expression profiling using an Ovarian Cancer Biomarker Nanostring panel
A custom NanoString 800 GX CodeSet was designed to measure gene expression of 800 biomarkers and controls that are associated with ovarian disease biology including subtype and prognosis classifiers, efflux ABC transporters, as well as chemo-tolerance, immune and angiogenesis markers (see Supplemental Table S1 for complete gene list). 200ng RNA was analyzed using the NanoString nCounter Analysis System following the manufacturer's protocol (NanoString Technologies). Output raw counts were normalized by the median counts of all 800 assays for each sample.
Statistical analysis
Progression-free survival was calculated from the date of randomization to the date of the first indication of disease progression or death, whichever occurred first; the data for patients who 7 were alive without disease progression were censored as of the date of their last non-PD tumor assessment. Overall survival was calculated from the date of randomization to the date of death from any cause; data for patients still alive were censored at the date the patient was last known to be alive. Survival analysis was carried out using log-rank test for the difference in the distribution of progression-free survival between the biomarker high and low groups. Median survival time was computed using the product-limit estimate by the Kaplan Meier method.
To compare gene expression differences between Plat-S and Plat-R primary tumors, twosample t tests were employed. To compare gene expression differences between Plat-R matched primary and metastatic tumors, paired t tests were used. Two-sided p values were derived and adjusted for multiple comparisons by controlling for FDR using the Benjamini Hochberg method.
RNA in situ hybridization (RNA ISH) assays
Duplex POSTN/LOX and single-plex FAP RNAscope® in situ hybridization (ISH) assays were designed, implemented and scored at Advanced Cell Diagnostics, Hayward, CA. The single color probe for FAP (NM_004460.2, nt 237-1549) was pre-designed and commercially available.
Dual color paired double-Z oligonucleotide probes were designed against LOX (GenBank accession number NM_001178102.1, nt 223-1725) and POSTN (NM_006475.2, nt 13-1199) RNA using custom software as described previously (11) . RNA ISH was performed using the RNAscope® 2-plex Chromogenic Reagent Kit and RNAscope® 2.0 HD Brown Reagent Kit on 4μm formalin-fixed, paraffin-embedded (FFPE) tissue sections according to manufacturer's instructions. RNA quality was evaluated for each sample with a dual colored probe specific to the housekeeping gene cyclophilin B (PPIB) and RNA polymerase subunit IIA (PolR2A). 
H&E assessment of desmoplasia
Representative H&E stained sections of the discovery tumor samples (85 total including primary Plat-S, patient-matched Plat-R primary and recurrent tumors) were examined for evidence of stromal activation associated with tumor insult and a desmoplasia score was assigned. Some cases were deemed too difficult to score due to tissue damage, necrosis, edema or limited stroma present. Desmoplasia was identified as fibrotic regions typified by an increased density and disorganization of myofibroblasts distinct from resident non-activated fibroblasts. The desmoplasia scoring system used is similar to that reported by Tothill et al in 2008 (8) .
Desmoplasia Scores were defined as follows: 0 = no desmoplasia, 1 = few scattered desmoplastic foci abutting cancer cells, 2 = several desmoplastic foci abutting cancer cells or moderate confluent (wider) desmoplasia, but not present throughout the section, 3 = desmoplastic reaction throughout section.
TP53 mutation status
We performed deep sequencing on all exons and exon-intron junctions of the entire TP53 gene using a previously developed MMP-Seq targeted cancer panel (12) . Quality of the FFPE DNA samples was quantified as number of functional copies using a TRAK2 qPCR "ruler assay" (12) . 5000 functional copies of DNA from each sample were used as the input for target enrichment and library construction using Fluidigm Access Array followed by deep sequencing on an Illumina MiSeq sequencer. The average coverage of TP53 gene was ~1000x per amplicon.
Sequence alignment, primary variant calling and filtering was performed as previously described (12) .
Results
Identification of a "reactive stroma" gene signature up-regulated in primary chemoresistant ovarian tumors
To identify molecular characteristics associated with primary chemoresistance in EOC, we characterized a set of high-grade serous and endometrioid ovarian tumors with clinically welldefined response to primary chemotherapy ( Table 1 , Materials and Methods). This discovery set consisted of tumor specimen from 32 patients with primary chemoresistance and 26 patients who were sensitive to primary chemotherapy. All patients were treated with a combination of platinum and taxane as the front-line chemotherapy. Twenty seven out of 32 chemoresistant patients had patient-matched primary tumor specimen collected prior to chemotherapy along with a recurrent tumor specimen collected at disease progression following chemotherapy (referred as Plat-R primary and Plat-R recurrent, respectively, in this report). For the 26 chemosensitive patients, only primary tumor specimens prior to therapy were available for analysis in this study (referred as Plat-S primary in this report).
We first explored whether we could identify a gene expression signature that associated with resistance to platinum-based chemotherapy. Gene expression profiling was performed on these samples using an 800-gene ovarian cancer biomarker panel (Materials and Methods, Supplementary Table S1) developed on the Nanostring platform (13) . Two-sample t tests comparing 32 Plat-R and 26 Plat-S primary tumors prior to chemotherapy identified 14 genes that are significantly differentially expressed between the two groups (FDR ≤ 10% and fold change ≥1.5, Supplementary Table S2) . Interestingly, up-regulated genes in the Plat-R tumors represented a distinct "reactive stroma" signature ( Figure 1A Table   S4 ). The observed overall high frequency of TP53 mutation is consistent with TCGA findings in high-grade serous ovarian tumors (17) and indicate that TP53 mutation status is likely not the main driver of chemoresistance. We also performed a qPCR-based copy number analysis on 35 genes that have been reported to be frequently altered in many types of cancer (Materials and Methods, Supplementary Table S5) . Nine recurrently amplified genes were identified in this study ( Figure 1A , copy number ≥ 4). Among these, RSF1, AKT1 and AKT3 amplification were only identified in Plat-S tumors, while FGFR1 and ZNF703 amplification were only identified in Plat-R tumors. However, no significant association was observed between response to chemotherapy and amplification of any one (including CCNE1) or combination of these genes.
The reactive stroma signature genes are derived and modulated specifically in tumor associated fibroblasts
To distinguish what specific cell types produced the reactive stroma signature genes, we tumors showed no detectable or very minimal protein or RNA expression for the reactive stroma signature genes products in stromal or tumor cells. In contrast, in Plat-R primary and recurrent tumors, we found that POSTN RNA and protein were exclusively expressed in the tumorassociated fibroblasts, while LOX and FAP were predominantly expressed in tumor-associated fibroblasts and at lower levels in tumor cells. The POSTN/LOX/FAP expressing tumorassociated fibroblasts also showed strong alpha-smooth muscle actin (αSMA) staining, which is an established marker of an activated myofibroblasts phenotype (18) . Consistent with the results from the Nanostring gene expression profiling ( Figure 1D ), ISH and IHC analysis confirmed expression of reactive stroma genes were significantly higher in Plat-R primary tumors compared to Plat-S primary tumors, and were further up-regulated in Plat-R recurrent tumors ( Figure 2B) . Importantly, the observed modulation of the reactive stroma genes was mostly restricted to the peritumoral stromal compartment in primary and recurrent Plat-R tumors ( Figure   2B ), highlighting the tumor associated stromal components as a potential specific site of action in mediating chemoresistance in ovarian cancer.
Stromal expression of POSTN is associated with a desmoplastic phenotype
Desmoplasia is a common pathological phenotype found in many types of cancer. Histologic manifestation of desmoplasia include significant overproduction of extracellular matrix proteins, and extensive proliferation and disorganization of myofibroblast-like cells (19) . Changes in stromal cell proliferation and the deposition of extracellular matrix components result in dramatic changes in overall tissue heterogeneity and elasticity, as well as accompanying interstitial fluid pressure. These changes have been suggested to contribute to chemoresistance in cancer (20, 21 in our discovery set were quantitated for the degree of desmoplasia. Twenty-six specimens were deemed too difficult to score due to tissue damage, necrosis, edema or limited stroma present.
The remaining specimens comprised 21 Plat-S primary, 18 Plat-R primary and 21 Plat-R recurrent tumors. As shown in Figure 3A&B , while no or only a few scattered desmoplastic foci were observed in the majority of the Plat-S primary tumors, the Plat-R primary and recurrent tumors were highly enriched for a moderate to high desmoplastic phenotype when compared to the Plat-S primary tumors. Furthermore, the degree of desmoplasia was highly correlated with stromal expression level of POSTN, one of the key components of the reactive stroma signature characterizing primary chemoresistance ( Figure 3A ).
POSTN promotes in vitro chemoresistance
One of the key component of the reactive stroma signature, POSTN, has been previously 
Independent validation of the reactive stroma signature in association with primary chemoresistance
To further validate the association between the reactive stroma signature and primary chemoresistance in an independent dataset, we utilized a subset of ovarian tumor tissue samples from the chemo-treatment arm of the ICON7 trial. The ICON7 phase III trial showed survival benefit from the addition of bevacizumab to standard doublet carboplatin-paclitaxel chemotherapy in front line treatment of ovarian cancer (25) . Among the 510 patients enrolled in the chemo-treatment arm, 138 patients with high-grade serous or endometrioid ovarian tumors had tissue available for gene expression profiling on the Nanostring ovarian cancer biomarker panel ( Table 2) . No significant biases in terms of the distribution of Plat-R and Plat-S patients, or clinicopathological characteristics were found in the biomarker evaluable population, and PFS in the biomarker evaluable population was similar to that in the overall intent to treat (ITT) population. These findings suggest the biomarker evaluable population is representative of the intention-to-treat (ITT) population (Supplementary Table S6 ). We categorized patients from ICON7 chemo-treatment arm into Plat-S and Plat-R groups using the same clinical definition as our discovery study. Two sample t-test analysis on 49 Plat-R and 86 Plat-S primary tumors prior to chemotherapy identified 10 genes that are significantly differentially expressed between the Table S7) . Comparison of the differentially expressed gene lists from ICON7 dataset and the discovery dataset showed that the four reactive stroma signature genes (POSTN, FAP, TIMP3 and LOX) from our discovery set were also the top four significantly up-regulated genes in the primary chemoresistance tumors in this ICON7 data set ( Figure 4A ). These results independently confirmed that the reactive stroma signature is a robust and reproducible biomarker of chemoresistance in EOC. Interestingly, expression of PGR was consistently down-regulated at least 2-fold in the chemoresistant group in both the discovery and the ICON7 datasets (p < 0.001 and fold change = 3.3 in the discovery dataset; and p = 0.0058 and fold change = 2 in ICON7), suggesting progesterone signaling may play an important role in mediating sensitivity to chemotherapies in ovarian cancer.
POSTN predicts clinical outcome of first line platinum-based chemotherapy in EOC
To examine whether the reactive stroma signature genes can predict clinical outcome of front line carboplatin-paclitaxel chemotherapy in EOC, we performed univariate survival analysis on the ICON7 chemo-control arm patients using each of the four pre-specified reactive stroma signature genes, POSTN, FAP, TIMP3 and LOX, as well as PGR. As shown in Figure 4B hand, association between FAP or LOX expression and PFS using a median cutoff was not statistically significant, but highly significant when using a 75%tile cutoff (HR = 2.2, 95% CI: 
Discussion
Despite the fact that a substantial fraction of patients are intrinsically resistant to chemotherapy, nearly all ovarian cancer patients receive first line platinum/taxane-based treatment regimen to date as the standard of care. Ability to identify patients who gain little benefit from primary treatment is one of the highest priorities in ovarian cancer research, and an important step toward achieving improved treatment strategies in EOC patients (26) . Several previous studies have reported gene signatures associated with response to platinum-based therapy (27) (28) (29) ; however, validation of many of these signatures across studies has been difficult (30) . In addition, the mechanisms and functional characterization of these chemoresistance signatures have also been lacking. To date, no biomarkers for prediction of response to therapy are yet in clinical use.
In this study, we carried out a systematic and in-depth analysis to discover, functionally characterize and independently validate the key molecular characteristics associated with chemoresistance to primary carboplatin-paclitaxel treatments. One of the key strengths of this study is the high quality and clinically well annotated tumor tissue samples used for both the discovery and independent validation studies. For discovery, we explicitly selected a set of patients with clinically well-defined response to primary chemo-treatment and matched clinicopathological characteristics. For the independent validation study, we utilized the tissue samples from patients enrolled in the chemo-control arm of ICON7, a phase III clinical trial with representative ITT patient population and well-balanced clinical characteristics, well-annotated clinical response and patient outcomes. From the discovery study, we identified a reactive stroma signature to be specifically associated with the Plat-R primary tumors and were further up-regulated in Plat-R recurrent tumors. More importantly, we further validated this signature in an independent data set and demonstrated its clinical utility in predicting patient outcome for the 
front line platinum-based chemotherapy. Therefore, our findings provided a promising diagnostic strategy for identifying primary chemosesistant ovarian cancer patients. Further validation of the signature in both retrospective and prospective clinical trials will pave the way to utilizing a biomarker-based test for predicting response to primary chemotherapy in clinical care of ovarian cancer patients.
Another key advantage of this study is the in-depth characterization of the underlying biology of the identified reactive stroma signature genes, including characterizing their specific site of action in situ and recapitulating their functional role in vitro for mediating chemoresistance in EOC. Several previous studies have identified prognostic markers associated with survival (PFS and/or OS) in EOC (31) (32) (33) , including a few recently published studies on POSTN/collagen-remodeling/TGFβ-associated stromal signature predicts debulking status or poor survival in ovarian cancer (34) (35) (36) . However, none of these studies further characterized the direct role of these potential prognostic markers in modulating chemoresistance. In this study, using in situ analysis including both IHC and RNA ISH, we unambiguously identified that the reactive stroma signature genes were exclusively or predominantly produced by the activated fibroblast cells adjacent to the tumor cells. More importantly, we showed that modulation of the reactive stroma signature genes within the stromal components but not tumor cells were strongly correlated with the clinical chemoresistance. Importantly, we further demonstrated that chemosensitive ovarian cells grown in the presence of recombinant POSTN promoted resistance to carboplatin and paclitaxel treatment in vitro. To our best knowledge, our study provided the first strong evidence that POSTN, a key component of the reactive stroma, may play a specific role in orchestrating chemoresistance in ovarian cancer. Further dissection of molecular mechanism of POSTN in promoting chemoresistance is underway using a co-culturing system of 
ovarian cancer cell lines with either primary tumor associated fibroblast cells derived from ovarian cancer patients or conditioned media.
In addition to providing potential diagnostic strategy for identifying primary chemoresistant ovarian cancer patients, this study also provided important clues for further developing novel therapeutic strategies to overcome chemoresistance. For example, the specific association between reactive stroma, chemoresistance and poor clinical outcome identified from this study, highlighted the important interplay between cancer and the tumor microenvironment in ovarian cancer biology and treatment. Thus, targeting components of the tumor stroma in combination with agents directly targeting the tumor cells may provide a potential novel approach for overcoming resistance and improving efficacy. Indeed, up-regulation of POSTN has been observed in many cancer types, such as breast, lung, colon, pancreatic, and ovarian cancers (23) . A recent study has demonstrated that stromal POSTN is crucial for metastatic colonization by regulating the interactions between breast cancer stem cells (37) . Furthermore, targeting endogenous POSTN with a neutralizing antibody in an ovarian cancer cell line inhibited ovarian tumor growth and metastasis in animal models (38) . Taken together, the important roles of POSTN in cancer development, progression and treatment response make it a promising novel therapeutic target for overcoming chemoresistance. In addition to individual stromal components, our study has revealed that the reactive stroma signature characterizing chemoresistance is highly enriched in genes involved in the normal process of wound healing.
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